BTIG Remains a Buy on Masimo (MASI)
BTIG analyst Marie Thibault reiterated a Buy rating on Masimo (MASI – Research Report) today and set a price target of $178.00. The company’s ...
BTIG maintains Intuitive Surgical buy with $561 target
Intuitive Surgical (NASDAQ:ISRG) shares maintained their Buy rating and a $561.00 price target from BTIG, despite potential ...
BTIG reiterates Buy on Ideaya stock, cites significant updates
Tuesday, shares of Ideaya Biosciences (NASDAQ:IDYA), trading at $22.18 near its 52-week low of $22.10, drew attention as BTIG analysts maintained their Buy rating and $62.00 price target. According to ...
bovnews18h
Akebia Therapeutics Inc’s Stock Drama: Could This Be a Game-Changer for AKBA Investors?
Akebia Therapeutics Inc (AKBA) stock saw a modest uptick, ending the day at $2.07 which represents a slight increase of $0.14 or 7.25% from the prior close of $1.93. The stock opened at $1.95 and ...
bovnews19h
What’s Fueling Beyond Air Inc (XAIR) Stock’s -39.83% Loss Below Its 200-Day SMA?
Beyond Air Inc (XAIR) stock saw a modest uptick, ending the day at $0.42 which represents a slight increase of $0.05 or 13.51% from the prior close of $0.37. The stock opened at $0.4 and touched a low ...
Akebia price target raised to $10 from $5 at BTIG
BTIG raised the firm’s price target on Akebia (AKBA) to $10 from $5 and keeps a Buy rating on the shares. The firm cites the company’s Vafseo ...